Scientific Research News

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced o...

BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the World Vaccine Congress 2025 on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial infections and its applications in inflammatory diseases. The World Vaccine Congress took place in Washington, D.C. from April 22-24. Sepsis is a life-threatening com...

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Reproductive Partners Medical Group (RPMG), a leading fertility clinic in Southern California and proud member of the Ivy Fertility network, has been honored with two city proclamations, from Beverly Hills and Westminster, recognizing National Infertility Awareness Week (NIAW). This recognition shines a spotlight on the impact of infertility and the need for increased awareness, support, and equitable access to fertility care. National Infertility Awarene...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. In addition to a trial-in-progress study design update on the ongoing multicenter study Agni-01 (NCT06060613), Obsidian will share preclinical data from our cytoDRiVE® platform demonstrating spatiotemp...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis, today announced it will present compelling data on NPX125, its lead B7-H7-targeting antibody-drug conjugate (ADC) with a proprietary novel linker technology, at the American Association for Research (AACR) Annual Meeting 2025 in Chicago. NPX125, which utilizes NextPoint's proprietary linker...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the comb...

MUNICH--(BUSINESS WIRE)--CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug conjugates (ADCs). The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in Chicago, IL, April 25-30, 2025. The poster will highlight the potential of targeting Growth Differentiation Factor 15 (GDF-15) to enhance the activit...

SEATTLE--(BUSINESS WIRE)--Talus Bioscience, a technology-enabled therapeutics company, today announced new preclinical data from programs targeting transcription factors in chordoma, non-small cell lung cancer, and advanced prostate cancer. The data, presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held April 25-30, support Talus Bio’s first-in-class approach to target previously undruggable transcription factors using regulome-scale discovery in live human...

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma Presents New Data at AACR 2025 Highlighting N17350, a Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway...

TORONTO & PHILADELPHIA--(BUSINESS WIRE)--Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting...